Download PDF
Synlett 2019; 30(10): 1237-1240
DOI: 10.1055/s-0037-1611829
letter
© Georg Thieme Verlag Stuttgart · New York

Intramolecular Aldol Ring Closures of Cysteine Derivatives Leading to Densely Functionalised Pyroglutamates

Hadia Almahli
,
Niamh C. Jimenez
,
Mark G. Moloney*
The Department of Chemistry, Chemistry Research Laboratory, The University of Oxford, 12 Mansfield Road, Oxford OX1 3TA, UK   Email: mark.moloney@chem.ox.ac.uk
› Author AffiliationsA.H. gratefully acknowledges the award of a Council for At-Risk Academics (CARA) Fellowship and Christ Church College, University of Oxford, and N.J. acknowledges funding from EPSRC SBM CDT.
Further Information

Publication History

Received: 08 March 2019

Accepted after revision: 26 April 2019

Publication Date:
13 May 2019 (online)

    Permissions and Reprints All articles of this category


Abstract

The synthesis of densely functionalised pyroglutamates derived from cysteine by an aldol cyclisation strategy has been achieved.

Key words

aldol reaction - cyclization - heterocycles - pyroglutamate - lactams

Supporting Information

    Supporting information for this article is available online at https://doi.org/10.1055/s-0037-1611829.
  • Supporting Information
 

  • References

  • 1 Panduwawala TD, Iqbal S, Tirfoin R, Moloney MG. Org. Biomol. Chem. 2016; 14: 4464
    CrossrefPubMed
    • 2a Anwar M, Moloney MG. Chem. Biol. Drug Des. 2013; 81: 645
      CrossrefPubMed
    • 2b Anwar M, Cowley AR, Moloney MG. Tetrahedron: Asymmetry 2010; 21: 1758
      Crossref
    • 2c Anwar M, Moloney MG. Tetrahedron Lett. 2007; 48: 7259
      Crossref
  • 3 Andrews MD, Brewster AG, Crapnell KM, Ibbett AJ, Jones T, Moloney MG, Prout K, Watkin D. J. Chem. Soc., Perkin Trans. 1 1998; 223
  • 4 Andrews MD, Brewster AG, Moloney MG. Synlett 1996; 612
    Article in Thieme Connect
  • 5 Angelov P, Chau YK. S, Fryer PJ, Moloney MG, Thompson AL, Trippier PC. Org. Biomol. Chem. 2012; 10: 3472
    CrossrefPubMed
  • 6 Heaviside EA, Moloney MG, Thompson AL. RSC Adv. 2014; 4: 16233
    Crossref
  • 7 Andrews MD, Brewster AG, Moloney MG. J. Chem. Soc., Perkin Trans. 1 2002; 80
  • 8 Ishihara J, Hatakeyama S. Chem. Rec. 2014; 14: 663
    CrossrefPubMed
  • 9 Moloney MG, Trippier PC, Yaqoob M, Wang Z. Curr. Drug Discovery Technol. 2004; 1: 181
    CrossrefPubMed
    • 10a Satoh N, Yokoshima S, Fukuyama T. Org. Lett. 2011; 13: 3028
      CrossrefPubMed
    • 10b Nguyen H, Ma G, Gladysheva T, Fremgen T, Romo D. J. Org. Chem. 2011; 76: 2
      CrossrefPubMed
    • 10c Nguyen H, Maz G, Romo D. Chem. Commun. 2010; 46: 4803
      CrossrefPubMed
  • 11 Ma G, Nguyen H, Romo D. Org. Lett. 2007; 9: 2143
    CrossrefPubMed
  • 12 Moloney MG, Yaqoob M. Tetrahedron Lett. 2008; 49: 6202
    Crossref
  • 13 Method for aldol cyclisation: To a solution of N-acylated thiazolidine (1.0 equiv) in methanol was added sodium methoxide (1.05 equiv) and the resulting mixture was stirred at r.t. for 15–24 h. Subsequently, the mixture was partitioned between Et2O and 1 M HCl. The Et2O layer was washed with brine, dried (MgSO4), filtered and concentrated in vacuo to furnish the crude pyroglutamates. Methyl (3R,7R,7aR) and (3R,7S,7aR)-3-(tert-butyl)-7-hydroxy-7-methyl-5-oxodihydro-1H,3H-pyrrolo[1,2-c]thiazole-7a(5H)-carboxylate (7a and 8a). Yellow oil. IR: 2958, 1739, 1688, 1616, 1366, 1260, 1108, 1022 cm–1. 1H NMR (500 MHz, CDCl3): δ (major) = 5.11 (s, 1 H, H-3), 3.80 (s, 3 H, CO2Me), 3.62 (d, J = 12.1 Hz, 1 H, H-1), 3.55 (d, J = 12.1 Hz, 1 H, H-1), 3.04 (d, J = 16.3 Hz, 1 H, H-6), 2.45 (d, J = 16.3 Hz, 1 H, H-6), 1.27 (s, 3 H, H-9), 0.93 (s, 9 H, t-Bu); δ (minor) = 5.07 (s, 1 H, H-3), 3.82 (s, 3 H, CO2Me), 3.69 (d, J = 12.9 Hz, 1 H, H-1), 3.27 (d, J = 12.9 Hz, 1 H, H-1), 3.23 (d, J = 15.7 Hz, 1 H, H-6), 2.42 (d, J = 15.6 Hz, 1 H, H-6), 1.51 (s, 3 H, H-9), 0.93 (s, 9 H, t-Bu). 13C NMR (500 MHz, CDCl3): δ (major) = 175.3 (C-5), 172.0 (CO2Me), 85.0 (C-7a), 79.6 (C-7), 73.1 (C-3), 53.1 (CO2Me), 47.2 (C-6), 38.3 (C-10), 33.4 (C-1), 26.4 (t-Bu), 21.8 (C-9); δ (minor) = 173.6 (C-5), 172.4 (CO2Me), 84.2 (C-7a), 78.7 (C-7), 72.2 (C-3), 53.0 (CO2Me), 46.7 (C-6), 38.3 (C-10), 33.8 (C-1), 26.4 (t-Bu), 24.04 (C-9). HRMS (ESI+): m/z [M + H+] calcd for C13H22NO4S+: 288.12641; found 288.12650. Methyl (3R,7S,7aR)-3-(tert-butyl)-7-hydroxy-6-methyl-5-oxo-7-((phenylthio)methyl)-hexahydropyrrolo[1,2-c]thiazole-7a(5H)-carboxylate (11b). Yield: 0.19 g (76%); yellow oil; [α] d 23 –19.8 (c 1.0 in CHCl3). IR: 3358, 2930, 2854, 1713, 1583 cm–1. 1H (500 MHz, CDCl3): δ = 7.19–7.23 (m, 5 H, ArH), 5.11 (s, 1 H, C(3)H), 3.79 (s, 3 H, OCH3), 3.75 (d, J = 16.2 Hz, 1 H, C(1)HAHB), 3.65 (d, J = 16.2 Hz, 1 H, C(1)HAHB), 3.22 (d, J = 16.2 Hz, 1 H, CHAHB), 3.10 (q, J = 7.2 Hz, 1 H, C(6)H), 3.07 (d, J = 16.2 Hz, 1 H, CHAHB), 1.07 (d, 3 H, CH3), 0.93 (s, 9 H, t-Bu). 13C (126 MHz, CDCl3): δ = 176.7 (C(O)), 172.1 (CO2Me), 126.8–129.4 (C(Ar)), 83.50 (C(7a)), 83.31 (C(3)), 72.85 (C(7)), 53.43 (OMe), 51.46 (OMe), 46.49 (C(6)), 41.11 (CH2), 38.40 (C(3)), 34.32 (C(CH3)3), 26.64 (C(CH3)3), 14.41 (CH3). HRMS (ESI): m/z [M+] calcd for C20H28NO4S2: 410.14543; found: 410.14539.
  • 14 Wang Y, Huang G, Hu S, Jin K, Wu Y, Chen F. Tetrahedron 2017; 73 (34) 5055
    Crossref
  • 15 Jeong Y.-C, Moloney MG. Synlett 2009; 2487
    Article in Thieme Connect
  • 16 Eto K, Yoshino M, Takahashi K, Ishihara J, Hatakeyama S. Org. Lett. 2011; 13 (19) 5398
    CrossrefPubMed